PF-6260933
- CAS NO.：1811510-56-1
- Empirical Formula: C16H13ClN4
- Molecular Weight: 296.75
- MDL number: MFCD30532622
- Update Date: 2026-01-26 13:56:28
What is PF-6260933?
Biological Activity
PF-6260933 is a MAP4K4 inhibitor with IC50 of 3.7 nM and good kinome selectivity.
in vitro
PF-06260933 treatment of human aortic endothelial cell (EC) robustly prevents TNF-α-mediated endothelial permeability in vitro , similar to MAP4K4 knockdown.
< b>
in vivo
In the mice model, PF-06260933 treatment does not alter plasma lipid content, although reductions in glucose levels are observed, which is consistent with whole-body-inducible Map4k4 knockout animals. PF-06260933 administration ameliorates further plaque development and/or promotes plaque regression in this animal model (46.0% versus 25.5%), and a reduction in plasma glucose as well as lipid content is also observed.
p>
Properties of PF-6260933
| Boiling point: | 483.8±40.0 °C(Predicted) |
| Density | 1.330±0.06 g/cm3(Predicted) |
| storage temp. | Store at -20°C |
| solubility | DMF: 1 mg/ml; DMSO: 1 mg/ml; Ethanol: insol; PBS (pH 7.2): insol |
| form | A solid |
| pka | 5.04±0.13(Predicted) |
| color | White to off-white |
Safety information for PF-6260933
| Signal word | Warning |
| Pictogram(s) |
 Exclamation Mark Irritant GHS07 |
| GHS Hazard Statements |
H302:Acute toxicity,oral H315:Skin corrosion/irritation H319:Serious eye damage/eye irritation H335:Specific target organ toxicity, single exposure;Respiratory tract irritation |
| Precautionary Statement Codes |
P261:Avoid breathing dust/fume/gas/mist/vapours/spray. P305+P351+P338:IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing. |
Computed Descriptors for PF-6260933
New Products
Mirtazapine Impurity C/Mirtazapine Lactam Impurity N,O-Dimethylhydroxylamine hydrochloride Tetrabutylammonium perchlorate N,N CARBONYL DIIMIDAZOLE 2-Amino-5-bromo-4-(trifluoromethyl)pyridine（RM for Indian lab) (RS)-beta-Amino-beta-(4-bromophenyl)propionic acid (R)-1-Benzyl-3-pyrrolidinecarbonitrile N-Nitroso hydroxy Cetrizine EP Impurity-A Noradrenaline EP Impurity D/Noradrenaline Methyl Ether Cetirizine EP Impurity A/Cetirizine CBHP Impurity Lantanoprost rc B Clidinium Bromide Impurity 2,2'-(5-methyl-1,3-phenylene)-di(2-Methylpropionitrile) 1-methyl amino-2,4-dinitro benzene 5-Methyl-1,3-benzenediacetonitrile 4-Fluorothiophenol (R)-BoroLeu-(+)-Pinanediol-CF3COOH 4-(5-amino-1-methyl-1h-benzoimidazol-2-yl)-butyric acid isopropyl ester. 3,4 Diethoxy Benzylcyanide 2-Chloro Benzylcyanide 3-chlorobenzyl cyanide 3,4 Dimethoxy Benzylcyanide valeronitrile 4-Bromo BenzylcyanideRelated products of tetrahydrofuran
![5-PyriMidinecarboxaMide, 4-[(2-Methylpropyl)aMino]-N-(phenylMethyl)-2-[4-[(tetrahydro-2H-pyran-3-yl)Methyl]-1-piperazinyl]-](https://img.chemicalbook.in/CAS/20150408/GIF/1332708-14-1.gif)
You may like
-
Bendamustine deschloroethyl acid ethyl ester 2517968-40-8 NLT 95%View Details
2517968-40-8 -
Acebutolol EP Impurity K NLT 95%View Details
74143-33-2 -
Clidinium Bromide Impurity NLT 95%View Details
.6581-06-2 -
192110-67-2 NLT 95%View Details
192110-67-2 -
Cetirizine EP Impurity A/Cetirizine CBHP Impurity NLT 95%View Details
59872-62-1 -
90717-17-2 Ketamine Impurity-C NLT 95%View Details
90717-17-2 -
.2005-04-1 N-Nitroso hydroxy Cetrizine EP Impurity-A NLT 95%View Details
.2005-04-1 -
145773-22-1 Lantanoprost rc B NLT 95%View Details
145773-22-1
Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.